UCB (UCBJY) Expected to Announce Earnings on Thursday

UCB (OTCMKTS:UCBJY) is expected to issue its resultson Thursday, July 30th. Analysts expect the company to announce earnings of $2.91 per share and revenue of $4.6424 billion for the quarter.

UCB Stock Performance

Shares of UCBJY stock opened at $139.06 on Thursday. The stock’s fifty day simple moving average is $143.74 and its 200 day simple moving average is $147.84. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. UCB has a one year low of $102.90 and a one year high of $168.76.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on UCBJY. Zacks Research raised UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Finally, Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, UCB presently has an average rating of “Hold”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.